Daniel G. Welch
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Nuvation Bio Named In Penny Stock Watchlists. Nuvation Bio (NUVB) has been included in recent lists of penny stocks to watch for October 2026. The company's shares are currently trading near a key support level of $4.75, which has been tested multiple times. This technical position provides context for its inclusion in these speculative stock lists.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
LLY Stock Dip News Unrelated to GPCR. Recent headlines focus on Eli Lilly (LLY) stock performance, which does not provide specific news about Structure Therapeutics (GPCR). While GPCR technical indicators show extreme oversold conditions, the provided news articles do not contain company-specific updates or developments for this symbol.
Transaction History
| RARE | ▲ Buy | Grant | 7,751 | $0 | 5/14/2026 | View on chart |
| RARE | ▲ Buy | Grant | 5,740 | $0 | 5/15/2025 | View on chart |
| RARE | ▲ Buy | Grant | 5,345 | $0 | 6/18/2024 | View on chart |
| NUVB | ▲ Buy | Option Exercise | 293,203 | $510K | 5/24/2024 | View on chart |
| NUVB | ▲ Buy | Option Exercise | 366,744 | $601K | 5/24/2024 | View on chart |
| RARE | ▲ Buy | Grant | 3,860 | $0 | 6/7/2023 | View on chart |
| GPCR | ▼ Sell | Other | 123,508 | — | 2/7/2023 | View on chart |
| RARE | ▲ Buy | Grant | 3,300 | $0 | 6/24/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
RARE FDA approves Fayuvi, triggers $203M voucher sale
Ultragenyx Pharmaceutical received FDA approval for its gene therapy Fayuvi. The approval was followed by a second sale of a priority review voucher, bringing in about $203 million within a week. The cash from the voucher sale adds to the company’s resources as it looks to expand its approved product portfolio. Analysts are evaluating whether the newly approved product can support the next growth phase.
RARE FDA approves Fayuvi, triggers $203M voucher sale. Ultragenyx Pharmaceutical received FDA approval for its gene therapy Fayuvi. The approval was followed by a second sale of a priority review voucher, bringing in about $203 million within a week. The cash from the voucher sale adds to the company’s resources as it looks to expand its approved product portfolio. Analysts are evaluating whether the newly approved product can support the next growth phase.